Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05016050 · ClinicalTrials.gov registry record · NA
Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)
A NA study, sponsored by Happify.
- Completed
- Registry status
- NA
- Development phase
- 367
- Enrollment target
NCT05016050 is a NA study that has completed, run by Happify. The registered enrollment target is 367 participants.
The verdict
NCT05016050, a NA study, has completed, sponsored by Happify.
- COMPLETED
- Registry status
- NA
- Development phase
- 367 participants
- Enrollment target
Study Summary
Participants with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) will use a prescribed digital therapeutic for 8-10 weeks, and will complete depression and anxiety measures during this time. After the treatment period, participants will be followed monthly for 12 months.
Interventions
- DEVICE HPDT-DA-013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2021-08-09 |
| Est. Completion | 2023-04-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05016050
The ClinicalTrials.gov registry entry for NCT05016050 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 367 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Happify, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HPDT-DA-013 is the first listed.
NCT05016050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05016050 about?
NCT05016050 is a clinical study titled "Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)". Participants with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) will use a prescribed digital therapeutic for 8-10 weeks, and will complete depression and anxiety measures during this time. After the treatment period, participants will be followed monthly for 12 months.
What is the current status of trial NCT05016050?
This trial is currently completed. It is a NA study. The enrollment target is 367 participants. The study started on 2021-08-09. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT05016050?
The interventions under investigation include: HPDT-DA-013 (DEVICE).
Who is sponsoring clinical trial NCT05016050?
This trial is sponsored by Happify, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.